BPC-157
A pentadecapeptide derived from a gastric protein, widely studied for soft tissue stability and recovery process research.
⏱ Half-Life
Short–Moderate duration profile
BPC-157 demonstrates a short–moderate half-life characteristic in research literature, shaping how observation windows and study timelines are typically structured.
⚡ Onset Characteristics
Moderate measurable response
Onset is observed as moderate — a property that influences how researchers structure comparative studies versus other compounds in the recovery research category.
🧠 Key Notes
What makes it distinct
- 01Notably stable across pH ranges in research conditions
- 02Frequently paired with TB-500 in literature
- 03One of the most cited recovery research peptides
🧬 Mechanism of Action
How it works
BPC-157 (Body Protection Compound) is a stable 15-amino-acid sequence isolated from a protective protein in human gastric juice. It modulates the nitric oxide (NO) system, upregulates VEGFR2 (driving angiogenesis), and accelerates fibroblast and tendon-cell proliferation. Unique among peptides, it remains structurally stable in gastric acid, allowing oral as well as injectable research administration. It also supports gut-barrier integrity, protects endothelial function, and modulates dopamine and serotonin signalling — giving it a broader systemic profile than purely localised repair peptides.
✨ Documented Benefits
What the research shows it supports
🔍 Research Insights
What the literature shows
Unusual stability in gastric acid makes it one of the few peptides studied via oral administration in animal models.
Modulates the nitric oxide system and VEGFR2 signalling, supporting angiogenic activity in repair research.
Hundreds of preclinical publications — one of the most heavily-studied repair peptides in the literature.
🧪 Typical Research Use Cases
Where it appears in study design
Tendon, ligament, and gut-lining repair models.
Vascular regeneration and microcirculation studies.
Oral vs injectable bioavailability comparisons.
📚 References
Peer-reviewed literature
Primary research sources cited on this profile. All links resolve to PubMed or the publishing journal.
- [01]
Sikiric, P. et al. (2018). Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation. Biomedicines, 6(4), 96.
Biomedicines ↗ - [02]
Chang, C. H., Tsai, W. C., Lin, M. S., Hsu, Y. H., & Pang, J. H. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780.
Journal of Applied Physiology ↗ - [03]
Seiwerth, S. et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design, 24(18), 1972–1989.
Current Pharmaceutical Design ↗ - [04]
Sikiric, P. et al. (2013). Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design, 19(1), 76–83.
Current Pharmaceutical Design ↗
Continue Exploring
Also explore: TB-500, GHK-Cu, MOTS-c
